Background: This study aimed to systematically review and meta-analyze published data on the diagnostic performance of 18 F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma, and to determine whether FDG-PET/CT can replace blind bone marrow biopsy (BMB) in these patients.
FDG-PET/CT may be a very useful method for bone marrow assessment in Hodgkin lymphoma and may potentially obviate the need for BMB. In the past few years, several studies have been published on the utility of FDG-PET/CT for bone marrow assessment in Hodgkin lymphoma. However, it is difficult to draw conclusions based on these individual studies, because the incidence of bone marrow involvement in Hodgkin lymphoma is relatively low (its incidence has been reported to vary between 4% and 14% [7] ), study quality may vary, and differences in patient population and study design may cause heterogeneity in study results. In order to overcome the shortcomings of individual studies, a systematic review and meta-analysis are required. The purpose of this study was therefore to systematically review and meta-analyze published data on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma, and to determine whether FDG-PET/CT can replace BMB in these patients.
methods search strategy
A computer-aided search of the PubMed/Medline and Embase databases was conducted to find relevant published articles on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in patients with newly diagnosed Hodgkin lymphoma. The search strategy is presented in Table 1 . No beginning date limit was used. The search was updated until 8 May 2013. To expand our search, bibliographies of articles that finally remained after the selection process were screened for potentially suitable references.
study selection
Studies investigating the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma were eligible for inclusion. No language restriction was applied. Review articles, meta-analyses, (conference) abstracts, editorials or letters, case reports, guidelines for management, studies including 10 or fewer patients, studies carried out in animals, and ex vivo studies were excluded. Studies that did not allow separate data extraction of newly diagnosed Hodgkin lymphoma patients from previously treated Hodgkin lymphoma cases or other nonHodgkin lymphoma cases were excluded. Only studies that used an integrated PET/CT system were included; studies that used a stand-alone PET system (i.e. without CT-based attenuation correction of PET data) were excluded. Studies in which the FDG-PET field of view included less than the area from the base of the skull to the pubic symphysis were excluded. If BMB was not used as ( part of the) reference standard, the study was also excluded. At this stage, studies that provided insufficient data to calculate the proportion of FDG-PET/CT-negative cases with a positive BMB among all cases were excluded. When data were presented in more than one article, the article with the largest number of patients or the article with the most details was chosen.
Titles and abstracts of the retrieved articles were reviewed, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The full-text versions of the remaining articles were then reviewed to determine their eligibility for inclusion.
study quality
The methodological quality of the included studies was assessed using the Revised Quality Assessment of Studies of Diagnostic Accuracy Included in Systematic Reviews (QUADAS)-2 tool [8] . QUADAS-2 evaluates the risk of bias and concerns regarding applicability for patient selection, index test, reference standard and risk of bias in the domain of study flow/timing. All included articles were analyzed in terms of patients (newly diagnosed Hodgkin lymphoma), index test (FDG-PET/CT), reference standard, and flow and timing. A study was scored 'L' for low risk of bias/low concerns regarding applicability, 'H' for high-risk/high concerns and 'U' for unclear for each domain. All domains with at least a negative response scored high risk of bias/high concerns regarding applicability, whereas domains with no negative responses but at least one unsure response scored unclear. Domains with no negative and no unsure responses scored low risk of bias/low concerns.
statistical analysis
As BMB can miss focal bone marrow involvement [9] [10] [11] [12] , BMB is not a suitable reference standard to calculate sensitivity and specificity of FDG-PET/ CT. Therefore, only studies that used at least both BMB and follow-up FDG-PET/CT studies as reference standard were included to determine the numbers of true-positive, false-positive, true-negative, and false-negative FDG-PET/CT cases in each individual study. Studies that only used BMB as reference standard were excluded from this analysis. Subsequently, sensitivities and specificities of FDG-PET/CT in individual studies were calculated. To determine whether researchers may have used different thresholds to define positive and negative test results (either explicitly or implicitly), the Spearman ρ between the logit of sensitivity and logit of 1 − specificity was calculated to assess the presence of a threshold effect. A strong positive correlation (Spearman ρ > 0.6) would suggest presence of a threshold effect [13] . If there was no threshold effect, pooled sensitivity and specificity of FDG-PET/CT were calculated using a random effects model. Subsequently, the results of the individual studies were displayed in receiver operating characteristic (ROC) space, and a weighted symmetric summary ROC (sROC) curve with a 95% confidence interval (95% CI) was computed with the Moses-Shapiro-Littenberg method [14] . Heterogeneity among the results of individual studies was tested by subjecting the diagnostic odds ratios (DORs) of individual studies to the Higgins and Thompson test, calculating the I 2 statistic [15] . Note that the DOR is a single overall indicator of diagnostic performance and is, unlike sensitivity and specificity, independent of any threshold value [16] . Heterogeneity was defined as I 2 > 50% [15] . If no heterogeneity was identified, no further subgroup analyses were carried out. Finally, the proportion of FDG-PET/CT-negative cases with a positive BMB among all cases was determined in each individual study. For this analysis, all included studies were used that allowed separate data extraction of FDG-PET/CT versus BMB alone. Heterogeneity across individual studies was assessed using the I 2 statistic, with heterogeneity defined as I 2 > 50% [15] . If no heterogeneity was identified, a fixed effects model was used to calculate the weighted summary proportion of FDG-PET/CT-negative cases with a positive BMB among all cases. 
results

literature search
The computer-aided search revealed 230 articles from PubMed/ Medline and 235 articles from Embase (Table 1) . After discarding duplicates, 419 articles remained and were screened on title and abstract for eligibility in this meta-analysis. Reviewing titles and abstracts from Embase revealed 49 articles potentially eligible for inclusion. After reviewing the full article, 23 articles were excluded because stand-alone FDG-PET was carried out rather than integrated FDG-PET/CT, 11 articles were excluded because they provided insufficient data to calculate the proportion of FDG-PET/CT-negative cases with a positive BMB among all cases, two studies were excluded because they enrolled <10 patients with Hodgkin lymphoma, two studies were excluded because of mixing newly diagnosed with previously treated Hodgkin lymphoma, one study was excluded because it only enrolled patients who were positive for bone marrow involvement at FDG-PET/CT, and one study was excluded because the same data were used in another article providing more study details. Thus, nine studies remained, comprising a total sample size of 955 patients with newly diagnosed Hodgkin lymphoma [17] [18] [19] [20] [21] [22] [23] [24] [25] . Seven of these nine studies used at least both BMB and follow-up FDG-PET/CT studies as reference standard, whereas two of these nine studies only used BMB as reference standard. Characteristics of included studies are shown in Tables 2 and 3 .
methodological quality assessment
The QUADAS-2 scores are displayed in Table 4 . The risk of bias for the index test and reference standard remained unclear in the majority of cases since these studies did not report whether the index test (six of nine studies) and/or reference standard (all studies) were interpreted in a blinded manner, and two of nine studies did not report the applied criteria for FDG-PET/CT positivity. There were no major concerns regarding the applicability of included studies.
diagnostic performance
Seven of nine included studies allowed calculation of sensitivity and specificity of FDG-PET/CT [17] [18] [19] [20] [22] [23] [24] . The sensitivity and specificity of FDG-PET/CT for the detection of bone marrow involvement ranged from 87.5% to 100% and from 86.7% to 100%, respectively (Table 5 ) [17] [18] [19] [20] [22] [23] [24] . Spearman ρ between the logit of sensitivity and the logit of 1 − specificity was −0.679 (P = 0.094), which suggested that there was no threshold effect. Pooled sensitivity and specificity of FDG-PET/ CT were 96.9% [95% CI 93.0% to 99.0%] and 99.7% (95% CI 98.9% to 100%), respectively ( Table 5 ). The area under the sROC curve was 0.9860 ( Figure 1 ). The DORs were homogeneous across individual studies (I 2 = 32.8%). Therefore, no further subgroup analyses were carried out. The proportions of FDG-PET/CT-negative cases with a positive BMB among all cases were homogeneous across all nine included studies (I 2 = 34.3%). The weighted summary proportion (fixed effects model) of FDG-PET/CT-negative patients with a positive BMB among all cases was 1.1% (95% CI 0.6% to 2.0%).
discussion
The Cotswolds report on the investigation and staging of Hodgkin lymphoma that was published in 1989, recommends to restrict BMB to patients with CT-based stage III/IV disease or stage II disease with adverse unfavorable factors, and only if a positive finding will change therapy planning [26] . Other guidelines, such as those issued by the European Society for Medical Oncology (ESMO) in 2011, advise to routinely perform BMB in all patients with Hodgkin lymphoma [1] . Not surprisingly, the use of BMB in newly diagnosed Hodgkin lymphoma varies considerably among different centers [27] . Given the controversy reviews regarding the need for BMB, and the potential of FDG-PET/ CT in assessing bone marrow status, it is being discussed whether FDG-PET/CT can obviate the need for BMB in these patients. It is difficult for individual studies to give a definitive answer to this question, because of the low incidence of bone marrow involvement in Hodgkin lymphoma [7] . In addition, a previous meta-analysis on this subject by Pakos et al. [28] that was published in 2005, suffered from a relatively low sample of patients with Hodgkin lymphoma, and included studies that used outdated stand-alone PET systems that have inferior contrast resolution compared with integrated PET/CT systems. The present systematic review and meta-analysis included nine studies, comprising a total of 955 patients with newly diagnosed Hodgkin lymphoma who all had undergone FDG-PET/ CT. Overall, methodological quality of included studies was moderate. Meta-analytically, FDG-PET/CT achieves very high sensitivity and specificity in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma ( pooled estimates of 96.9% and 99.7%, respectively). In addition, the chance of having a negative FDG-PET/CT but positive BMB is very low (weighted summary proportion of 1.1%). Results of individual studies were homogeneous and no threshold effect was detected, despite the fact that different studies used different criteria for positivity. These results not only indicate that FDG-PET/CT may replace BMB in newly diagnosed Hodgkin lymphoma, they also support the use of pretreatment FDG-PET/CT in these patients, which, according to guidelines such as those issued by the ESMO [1] is currently not regarded as mandatory.
In 2005, Vassilakopoulos et al. [7] introduced a clinical prediction rule for bone marrow involvement in Hodgkin lymphoma based on 826 patients and validated it in 654 additional patients. Independent prognostic factors for bone marrow involvement were B symptoms, stage III/IV before BMB, anemia, leukocytes fewer than 6 × 10 9 /l, age 35 years or older, and iliac/inguinal involvement. A prediction rule that included all these factors achieved sensitivity, specificity, positive predictive value, and negative predictive value of 98.1%, 40.3%, 12.7%, and 99.6%, respectively, in the validation group. Using this prediction rule, patients were divided into three different groups for risk of bone marrow involvement: low risk (44% of patients, 0.3% risk), standard risk (37% of patients; 4.2% risk), and high risk (20% of patients, 25.5% risk). It was concluded that patients with low risk (stage IA/IIA without anemia and leukopenia; stage IA/IIA, younger than 35 years, with either anemia or leukopenia but no inguinal/iliac involvement; and stage IIIA/IVA without any of these four risk factors) do not need BMB. On the other hand, it was recommended to stage patients with standard risk using unilateral BMB, and patients with high risk using bilateral BMB [7] . The results of the present meta-analysis show that, FDG-PET/CT is diagnostically superior (higher combined sensitivity and specificity) to the clinical prediction rule that was developed by Vassilakopoulos et al. [7] . Nevertheless, it may be useful to combine this clinical prediction rule with FDG-PET/CT to further optimize the diagnosis of bone marrow involvement. It should be realized that FDG-PET/CT is routinely carried out for staging newly diagnosed Hodgkin lymphoma in the majority of centers [5] , and, as such, does not result in additional costs.
The present meta-analysis had several limitations. First, included studies were of moderate methodological quality, and no large-scale prospective validation studies have been carried out. Second, included studies did not report sufficient information to assess the diagnostic value of FDG-PET/CT in early (i.e. stage I or II) and advanced (i.e. stage III or IV) Hodgkin Although bone marrow involvement in early stage disease is less common than in advanced stage disease [29, 30] , detection of bone marrow involvement in the former group is more likely to alter treatment than in the latter group. Third, included studies used a combination of different tests (among which pretreatment blind BMB of the iliac crest and follow-up FDG-PET/CT studies) as reference standard to determine bone marrow involvement, each with its limitations. Pretreatment blind BMB, although being very specific for bone marrow involvement, may suffer from sampling errors (i.e. false negatives) [9] [10] [11] [12] . Decrease in pathological bone marrow FDG uptake at follow-up FDG-PET/CT studies may be either because of responding lymphomatous bone marrow deposits, or due to resolution of benign bone marrow conditions such as bone marrow inflammatory changes (i.e. false positives) [31] . Nevertheless, because of the impossibility to histologically examine all bone marrow sites, the use of both pretreatment blind BMB and follow-up FDG-PET/CT as composite reference standard can be regarded as acceptable from a practical and ethical point of view. Fourth, therapeutic implications as a result of discrepancies between FDG-PET/CT bone marrow status and BMB result could not be determined. Fifth, cost-effectiveness of different diagnostic strategies for bone marrow evaluation (i.e. FDG-PET/CT alone versus BMB alone versus the combination of FDG-PET/CT with BMB) was not assessed.
In conclusion, although the methodological quality of studies that were included in this systematic review and meta-analysis was moderate, the current evidence suggests that FDG-PET/CT may be an appropriate method to replace BMB in newly diagnosed Hodgkin lymphoma.
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This project was financially supported by an Alpe d'HuZes/ Dutch Cancer Society Bas Mulder Award for TCK (grant no. 5409) and by a ZonMW AGIKO stipend for TCK (grant no. 92003497). Data collection, data analysis, and interpretation of data, writing of the paper, and decision to submit were left to the authors' discretion and were not influenced by Alpe d'HuZes/Dutch Cancer Society and ZonMW. introduction Currently, cervical cancer is the fourth leading cause of cancer death in women worldwide, causing more than 275 000 deaths annually. The disease has a very uneven global distribution; over 85% of cases are found in low-resource countries, with incidence and death rates being the highest in sub-Saharan Africa, Central America, South-Central Asia, and Melanesia [1, 2] . This imbalance in disease burden can be explained by differences in background risk [exposure to human papillomavirus (hrHPV) infection], and the fact that cervical cancer is preventable by an effective screening and intervention system. Therefore, the lowest incidence and mortality rates are recorded in countries where screening is available to women. The impact of population-based screening is reflected in a substantial reduction in the incidence of cervical cancer over the past 50 years in countries with established cytology-based screening programs [3] [4] [5] [6] . Especially, quality-assured population-based programs have shown to be very effective [6] . However, cytologybased cervical screening also has some limitations. The major problem is the low sensitivity of a single smear to detect highgrade precursor lesions (50%-70%), which require frequent testing [7] . In addition, cytology has low reproducibility, leading to variable accuracy [8, 9] . Moreover, by repeating cytology, the number of false positives increases substantially over time [10] . Finally, the decrease in the incidence of cervical cancer induced by cytologybased screening is mainly restricted to squamous cell carcinoma, whereas no change is observed in the incidence of cervical adenocarcinoma [11, 12] , suggesting that cytology fails to detect adenocarcinomas and its precursors. Consequently, there is a need for a better primary screening test, and thus a new screening algorithm.
human papillomavirus testing in the prevention of cervical cancer
cross-sectional sensitivity
Infection with hrHPV is a necessary event in the multistep process of cervical carcinogenesis [13] . Thirteen hrHPV types
